Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 12 member 2 (SLC12A2), also known as NKCC1, is a transmembrane protein that functions as an electroneutral cation-chloride cotransporter [1, 8]. It mediates the simultaneous transport of one sodium, one potassium, and two chloride ions across the plasma membrane, playing a fundamental role in maintaining intracellular chloride levels and regulating cell volume [11]. In the central nervous system, NKCC1 is highly expressed during early development, where it establishes the high intracellular chloride concentrations necessary for the excitatory actions of GABA, a process critical for neurogenesis and circuit formation [3, 13]. Beyond the brain, it is widely distributed in secretory epithelia, such as those in the inner ear, gastrointestinal tract, and exocrine glands, where it facilitates fluid and electrolyte secretion [1, 13]. Mutations in the SLC12A2 gene are associated with severe human pathologies, including Kilquist syndrome, sensorineural deafness, and various neurodevelopmental disorders [4, 9, 13]. Pharmacologically, SLC12A2 is a primary target for loop diuretics like bumetanide and furosemide, which are used clinically to treat edema and are being investigated for their potential to modulate neuronal excitability in conditions like neonatal seizures and autism [11, 17]. The transporter's activity is tightly regulated by phosphorylation via the WNK-SPAK/OSR1 signaling pathway in response to osmotic stress and changes in intracellular chloride [1, 11]. Therapeutic targeting of SLC12A2 requires careful consideration of its broad expression, as inhibition can lead to side effects such as ototoxicity and impaired secretion in exocrine glands [1, 13].
Inhibition of the Na-K-2Cl cotransporter (NKCC1), which blocks the electroneutral influx of sodium, potassium, and chloride ions into the cell [11].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 12 member 2 (SLC12A2) (SLC12A2).